Simcere Pharmaceutical Group is an emerging leader in developing, manufacturing, and marketing pharmaceutical products in China. It has over 3,000 sales reps covering over 3,000 hospitals and 70,000 retail pharmacies. Simcere focuses on five therapeutic areas and has differentiated products with market leadership in oncology and neuroscience. It has strong R&D capabilities and pursues an externalization strategy through licensing, collaborations, and acquisitions to develop a sustainable pipeline.

1. Simcere Pharmaceutical Group
Emerging Leader in Developing, Manufacturing and
Marketing of pharmaceutical products in China
September 2011
1

2. Disclaimer
 The information contained in this presentation does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer
to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment
whatsoever. Any public offering of the securities to be made in the United States will be made solely by means of the prospectus in the registration
statement. The prospectus contains detailed information about the Company and its management as well as the financial statements of the Company.
Any decision to purchase securities in the offering for sale in the United States or anywhere else should be made solely on the basis of the information
contained in the prospectus. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect
to the risks and special considerations involved with an investment in the securities of the Company, and is qualified in its entirety by reference to the
detailed information appearing in the prospectus.
 This presentation contains forward-looking statements, including statements about the Company’s business outlook, our strategy and market opportunity,
and statements about the Company’s historical results that may suggest trends for its business. These statements are individually and collectively
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are made only as of the date of this presentation and the Company undertakes no obligation to update or revise.
These statements are based on estimates and information available to the Company at the time of this presentation and are not guarantees of future
performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Therefore, prospective investors are cautioned
that actual results may differ materially from those set forth in any forward-looking statements herein.
 The information contained in these slides has not been independently verified. No representation or warranty, express or implied, is made as to, and no
reliance should be placed on, the fairness, accuracy, completeness or correctness of any information or opinion contained herein. The information
contained in these slides should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to
reflect material developments which may occur after the date of the presentation. None of the Company, any underwriter of securities of the Company, or
any of their respective directors, officers, employees, agents or advisers shall be in any way responsible for the contents hereof, or shall be liable for any
loss arising from use of the information contained in this presentation or otherwise arising in connection therewith.
 Before you invest, you should read the prospectus in the registration statement the Company filed with SEC and other documents the Company has filed
with the SEC for more complete information about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC
Web site at www.sec.gov. Alternatively, you may request the prospectus by sending us a request via our website at www.simcere.com.
2

3. Company Snapshot
 Publicly listed on NYSE, with highest standard of corporate compliance and transparency
 ~3000 sales reps and 1,500 distributors, covering over 3,000 hospitals and 70,000 retail
pharmacies
 Leading R&D capabilities in China ranging from early stage discovery to clinical operations
 8 GMP facilities supporting small molecule, biologics, and vaccine manufacturing
3

4. A Leader in China’s Pharmaceutical
Industry
Revenue (M, RMB)
2,500
Ranking:
2141
2,000
1850
#21 in Net Profit in
1741 China
healthcare
1,500 industry*
1369
#7 among the Top
1,000 951 20 most
competitive
737
public listed
564
466
healthcare
500
304
companies in
China
0
2002 2003 2004 2005 2006 2007 2008 2009 2010
* 2009 Chinese Medical Statistical Yearbook by Ministry of Industry and Information Technology of PRC
4

5. Key Strategy
 Focus on five therapeutic areas in the mid to high-end markets
 Oncology, Neuroscience, Cardiovascular, Inflammation, and Infectious
Disease
 Leveraged on deep channel penetration and branding advantage to
expand generic market
 Strengthening in-house R&D capabilities and cross boarder
collaboration to develop products quickly and effectively
 Executing Our Product-Oriented M&A Strategy
5

6. Differentiated Products with Market Leadership in
Oncology and CNS
Therapeutic Area Brand Name Product
Endu Proprietary recombinant human endostatin injection, NSCLC
Jiebaishu Nedaplatin injection
Oncology Sinofuan 5FU sustained release implant
Jiebaili Pemetrexed
Lowvo Palonosetron
Neuroscience Bicun/Yidasheng Edaravone injection, ischemic stroke
Xinta Levamlodipine besylate tablets, hypertension
Cardiovascular
Shufutan Rotuvastain generics, hyperlipidemia
Infectious Disease Anxin Biapenem injection, bacterial infection
I
Yingtaiqing Diclofenac sodium delayed release capsules , arthritis pain
nflammation
6

7. Strong Commercial Muscle and Deep Channel
Penetration
Proven Ability To Quickly
- Select and Position Product - Generate Strong Sales - Build Up Brand and Loyalty
• Collaborating with distributors who have direct selling to the end customers
• Continuing to build up our well trained professional sales team
• Cooperating with nation wide top drug store chains
• Seeking opportunities to leverage on the healthcare reform
Large field force with broad geographical reach
Over 3,000 hospitals Over 70,000 retail
pharmacies
7

8. Diversified R&D Strategy to Deliver
Sustainable Pipeline
Approaches Therapeutic Treatment
Areas Modalities
• Branded generics
• First-to-market • Oncology • Small molecules
generics • Neuroscience • Biologics
• Biosimilar • Cardiovascular • Peptides
• Novel: best-in- • Infectious disease
class • Vaccines
• Inflammation
8

9. With Increasing Focus on Novel Products
Category Contribution to Revenue
2005 2006 2007 2008
9

10. Endu: Proprietary Molecular Targeted
Therapy for NSCLC
 rh-Endostatin with nine
additional AAs at the N-
terminus (Endostar)
Stable at low pH (2.5) and at
high temperature (100 ℃)
Solubility: >15 mg/ml
Shelf life: 18 months at 4 ℃
 Manufactured in E. coli
Large-scale inclusion body
refolding
0.5 mg/ml, with >50% Endostatin Endu(Endostar)
recovery
10

11. Pipeline Overview
Therapeutic Status
Key Product
Areas Candidate Lead Lead Pre-
IND
Phase Phase Phase New Drug
Discovery Optimization clinical I II III Application
Inflammation Iguratimod tablets Approved
Oncology Oxaliplatin
Oncology Endu combined with NP Therapy
Cardiovascular rh-RGD-Hirudin for injection
Oncology Bendamustine for injection
Cardiovascular Oral fixed dose combination of
amlodipine & irbesartan
SIM-0930 (protein tyrosine kinase
Oncology
inhibitor)
Oncology
SIM6802 (protein tyrosine kinase IND approved
inhibitor)
SIM010603 (protein tyrosine
Oncology
kinase inhibitor)
Oncology SIMBD0801 (MAb)
Cerebrovascular SIM071201
Oncology SIM0710 (PEG-Endostar injection)
Onclogy SIM-817378

12. Simcere R&D Organization
Institute of Recombinant
Institute of Institute of Institute of Institute of Proteins R&D
Discovery Chem., Pharm. Shanghai
Discovery Biologics Vaccine Center
Chemistry & Anal. R&D Center
Biology Research Research
Development
Shanghai Yantai
Prof. Xiaojin Yin, Nanjing Nanjing
Nanjing
Nanjing Nanjing
Beijing
SVP
Dr. Peng Wang,
CSO Dept. of Market Dept. of
Institute of Office of Dept. of Regulatory Dept. of
Res. and
Clinical Intellectual Project Affairs Operation &
Business
Research Properties Management HR
Development
Nanjing
Nanjing Nanjing Nanjing Nanjing
Nanjing Beijing
 A staff of ~300, located in Nanjing, Shanghai, Beijing and Yantai
 PhD: ~20%; MS: ~60%; 25 staff members with Western training/working experience
 Ongoing aggressive recruitment of industrial veterans from US in all R&D areas
 Nanjing R&D Center: 200,000 sf
 7% of total revenues as R&D budget

13. Strong Track Record
 Clinical development:
 Over 30 successfully completed clinical trials
 Endu Ph IV trial completed in Dec. 2009, with >3,000 patients recruited, the largest clinical
study in China history
 Regulatory affairs:
 Approximately 100 NDAs/ANDAs obtained
 Five (5) INDs filed in 2010 alone
 A FIH trial in Australia completed
 Endu has been re-registered for marketing authorization in 2010: the first in China
 New head of Regulatory Affairs, Mr. Bo Xu (a former SFDA reviewer), has been on board
since 2010
 ~120 patents and patent applications
 Over 100 scientific publications
13

14. Externalization Critical to Overall
R&D Strategy
Internal
Programs
Licensing and
Collaboration M&A
14

15. Selected Key Partnerships
Innovative Strategic Partnership Traditional In-Licensing
 Joint Venture partnership with Merck (2011):  OSI Pharmaceutical (2009):
 A transformational deal that cements Simcere’s  A small molecule protein kinase inhibitor in Phase I
leadership in branded generics market in China development
 A strategic partnership with development,  Simcere responsible for development and commercialization
registration, manufacturing and sales capabilities in China
 Initial focus on cardiovascular and metabolic  OSI responsible for ex-China global development
diseases
 R&D strategic partnership with BMS (2010):
 Epitomics (2009):
 Co-development partnership
 A humanized rabbit monoclonal antibody in preclinical
 A small molecule oncology compound in preclinical development
development
 Simcere responsible for development and commercialization
 Simcere responsible for development and in China
commercialization in China
 Simcere and Epitomics to share cost of development
 BMS has option to resume global development (ex- outside of China
China) after Simcere achieves PoC in man
 GSK (2006):
 Simcere licensed the rights to develop an authorized generic
version of Relenza in China
 Product approved in China in 2010
15

16. Key Areas of Partnering Interests
 Oncology Flexible deal
 Molecular targeted therapies of both small molecules and biologics structures
based on validated or novel mechanism of action  Aim to create win-
 Cytotoxics differentiated on efficacy and/or tolerability with proof-of- win partnership
concept in man  Structure deals to
 Early stage opportunities and novel technology platforms that lead to fit partner’s
step change in cancer therapy strategy
 Neuroscience  Committed to
fostering growth
 Cerebrovascular disease treatment and neuroprotectant and sharing
 Alzheimer’s Disease – disease-modifying therapies with proof-of- success
concept in man Efficient process
 Cardiovascular and Metabolic Disease  Identify and
 Atherosclerosis, thrombosis, anti-coagulation, anti-platelet, atrial evaluate
fibrillation agents and diabetes opportunity
 Infectious Diseases  Conduct due
 Antibacterias that address bacterial resistance and serious infections diligence and
 Antifungals negotiate
agreement
 Antivirals – HBV and HCV only
 Implement and
 Inflammation
manage project,
 Rheumatoid Arthritis – disease modifying agents with potential to moving toward
differentiate based on efficacy and/or cost of treatment success
16

17. Value Proposition to Partners
 Leverage Simcere’s internal R&D capability to develop partner’s asset in
China under the FDA and SFDA requirements
 Accelerate clinical trials indications through faster patient enrollment
 Generate critical data package to support global development
 Leverage Simcere’s powerful commercial platform to achieve rapid and
broad market access
 Utilize Simcere’s experience, resources, leadership and homeland
advantage to penetrate the market
17

18. Simcere’s Commitment
 Clear corporate mandate of externalization
 Bring products to address significant unmet medical needs in China
through sourcing global innovations
 Commitment to fostering partnership and sharing success
 Flexible deal structures
 Highest standard of corporate compliance and transparency
 Experienced management team with proven track record
 World-class R&D leadership team with U.S. industry veterans
 Clinical Advisory Board with leading thought leaders in the U.S.
18